Phase II Trial of IUD in Conservative Management of Endometrial Cancer with Shannon Westin

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Shannon Westin to discuss Phase II Trial of IUD in conservative management of endometrial cancer. Dr. Westin focuses on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies. She currently serves as the Director of Early Drug Development and Phase I trials in her department and is a Co-Director of the Ovarian Cancer Moonshot. She is currently the PI or co-PI for greater than 30 novel treatment trials in gynecologic malignancies. Shannon Westin (@ShannonWestin / @mdandersonnews) Highlights: 1. A fertility-sparing, non-surgical approach is increasingly necessary for individuals diagnosed with early endometrial neoplasia due to increasing prevalence of significant comorbidities and proportion of premenopausal women diagnosed with this disease. 2. Out of 57 treated patients, 47 were evaluable and 12-month response rate was 83% overall (90.6% for complex atypical hyperplasia and 66.7% for grade 1 endometrioid endometrial cancer). 3. Adverse events associated with the IUD were mild, and quality of life was not negatively impacted.

4. This study used a rigorous 12-month endpoint to demonstrate durable response rates in women with early endometrial neoplasia and identified potential biomarkers for therapy resistance.